Cellectar Biosciences (id:6114 CLRB)
1.58 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 3:33:12 PM)
Exchange closed, opens in 1 day 17 hours
About Cellectar Biosciences
Market Capitalization 86.81M
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
| Headquarters (address) |
100 Campus Drive Florham Park 07932 NJ United States |
| Phone | 608 441 8120 |
| Website | https://www.cellectar.com |
| Employees | 20 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | CLRB |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.39 - 4.45 |
| Market Capitalization | 86.81M |
| P/E trailing | -0.508 |
| P/E forward | -0.756 |
| Price/Book | 16.85 |
| Beta | 1.01 |
| EPS | -2.43 |
| EPS United States (ID:6, base:3402) | 24.25 |